98%
921
2 minutes
20
The incidence of multidrug-resistant Acinetobacter baumannii has posed a major challenge for clinical treatment. There is still a significant gap in understanding the mechanism causing multi-drug resistance (MDR). In this study, the genomes of 10 drug sensitive and 10 multi-drug resistant A.baumannii strains isolated from a hospital in China were sequenced and compared. The antibiotic resistance genes, virulence factors were determined and CRIPSR-Cas system along with prophages were detected. The results showed that MDR strains are significantly different from the drug sensitive strains in the CARD entries, patterns of sequences matching up to plasmids, VFDB entries and CRISPR-Cas system. MDR strains contain unique CARD items related to antibiotic resistance which are absent in sensitive strains. Furthermore, sequences from genomes of MDR strains can match up with plasmids from more diversified bacteria genera compared to drug sensitive strains. MDR strains also contain a lower level of CRISPR genes and larger amount of prophages, along with higher levels of spacer sequences. These findings provide new experimental evidences for the study of the antibiotic resistance mechanism of A. baumannii.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.micpath.2022.105492 | DOI Listing |
Acta Parasitol
September 2025
Région du Centre, Université Joseph Ki-Zerbo, Rue Thomas Sankara, O3 BP 7021, Ouagadougou, Burkina Faso.
Introduction: The objective of the World Health Organization is to achieve the interruption of human African trypanosomiasis (HAT) transmission by 2030.
Methods: This review aims to update knowledge on HAT, through a synthesis on the epidemiology, diagnostic tools and drugs of HAT.
Results: From 1960 to 2024 approximately 132,063 cases of HAT have been reported across Africa.
Radiology
September 2025
Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea.
Background The optimal surgical management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer with calcifications remains controversial, particularly when pathologic complete response (pCR) is suspected. Purpose To identify factors associated with pCR after neoadjuvant chemotherapy in patients with HER2-positive breast cancer and assess whether calcifications affect the performance of radiologic complete response (rCR) at MRI for predicting pCR. Materials and Methods This retrospective study included patients with HER2-positive breast cancer who received neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab and underwent surgery between January 2021 and October 2023.
View Article and Find Full Text PDFJ Cosmet Dermatol
September 2025
Department of Medicine, Yazd Branch, Islamic Azad University, Yazd, Iran.
Background: Melasma is a prevalent skin condition that primarily affects females of reproductive age. Despite the various available treatments, managing melasma is challenging due to frequent relapses and partial responses. Tranexamic acid (TXA) has gained attention as a potential treatment because of its antifibrinolytic and anti-melanogenic properties.
View Article and Find Full Text PDFJ Viral Hepat
October 2025
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Discontinuing antivirals in chronic hepatitis B virus (HBV) 'e' antigen negative infection can enhance HBV surface antigen (HBsAg) loss but risks complications. We modelled the clinical impact of discontinuing antivirals in chronic HBV. We developed a Markov state model with Monte Carlo simulation of chronic HBV to compare continuation of antiviral therapy with 3 strategies of cessation and reinitiation for: (1) virologic relapse, (2) clinical relapse, or (3) hepatitis flare.
View Article and Find Full Text PDFBackground: This study aimed to evaluate the predictive value of combining the Padua score with D-dimer levels for identifying lower extremity deep vein thrombosis (DVT) in acute ischemic stroke (AIS) patients undergoing intravenous thrombolysis with alteplase.
Methods: This retrospective study analyzed clinical data from 632 AIS patients who received alteplase treatment at our hospital between September 2019 and October 2023. After applying strict inclusion and exclusion criteria, a total of 172 patients were included in the analysis: 35 patients in the DVT group and 137 patients in the non-DVT group.